A new review links GLP-1 drugs like Ozempic to potential blindness, but will this actually impact the demand for weight loss and diabetes medications? Despite the risks, the GLP-1 train shows no signs of slowing, raising serious questions about public health, regulatory oversight, and long-term safety concerns.
#ozempic #glp1 #podcastclips
